The Fazekas Scale: A Visual Grading System for White Matter Hyperintensities
The Fazekas scale is a widely used visual rating system that grades white matter hyperintensities (WMH) on T2-weighted or FLAIR brain MRI sequences from 0 to 3, with higher scores indicating greater severity of cerebral small vessel disease. 1
How the Fazekas Scale Works
The Fazekas scoring system provides a qualitative assessment of WMH burden visible on MRI, distinguishing between periventricular and deep white matter changes:
- Grade 0: No white matter lesions
- Grade 1: Punctate foci or "caps" of white matter hyperintensity
- Grade 2: Beginning confluence of lesions
- Grade 3: Large confluent areas of white matter hyperintensity
Clinical Application and Reliability
The scale demonstrates good inter-reader reliability across different clinical populations. In a recent study of sickle cell disease patients, the observed agreement between independent neuroradiologists was 94.44% with a Cohen's weighted kappa of 0.78, indicating substantial reliability 2. This reliability makes it practical for routine clinical use, though it remains somewhat subjective compared to volumetric methods 3.
Relationship to Quantitative WMH Volume
Recent research has established clear volumetric correlates for each Fazekas grade, enabling bidirectional translation between visual scores and quantitative measurements:
Volumetric ranges by Fazekas score 4:
- Fazekas 1: 0.1-8.3 mL (mean 3.7 mL)
- Fazekas 2: 6.0-17.7 mL (mean 10.8 mL)
- Fazekas 3: 14.2-77.2 mL (mean 35.2 mL, or 27.1 mL excluding outliers >50 mL)
The relationship between Fazekas scores and WMH volume follows an exponential rather than linear trajectory 5. This means WMH burden accelerates disproportionately at higher Fazekas grades. The widest transition zones occur between grades 3-4 and 4-5, while a clear volume gap separates grades 5 and 6 5.
Important Clinical Considerations
Standardization Recommendations
Current guidelines emphasize the need for standardized WMH assessment 1:
- Report global scores to facilitate cross-study comparison
- Distinguish periventricular from deep WMH when possible, as baseline periventricular WMH may be particularly important in MCI populations
- For severe WMH classification in small cohorts, utilize Fazekas scoring; for large population studies, consider upper quartile or z-scores >1
- Log transformation of WMH volumes and correction for total intracranial volume should be performed consistently
Common Pitfalls
- Subjectivity at lower grades: Reliability is overall lower and sometimes nonsignificant for patients with low WMH volumes, particularly when using manual volumetric methods 3
- Sequence dependency: The Fazekas scale can be applied to both T2 and FLAIR sequences, but FLAIR typically provides better contrast for periventricular lesions
- Population variability: The exponential progression of WMH burden is population-dependent, with adjacent-grade separation varying across different disease severities 5
Clinical Significance
WMH burden increases substantially with age and vascular risk factors. In Middle Eastern populations, prevalence rises from 18.2% in ages 40-50 to 54.1% in ages 60-70 6. Hypertension emerges as the strongest independent vascular predictor of cerebral small vessel disease 6, and certain antihypertensive classes (particularly calcium channel blockers and ACE inhibitor/ARB monotherapy) are associated with lower odds of CSVD compared with untreated hypertension.
Higher Fazekas scores correlate with increased cerebrospinal fluid volume, brain atrophy (particularly frontal and parietal lobes), and atrophy in specific subcortical structures including the accumbens and thalamus 7.